To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 423 participants.

Also called NCT05702073

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 423 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05702073
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05702073. Randomized; no masking; primary purpose treatment. Start 2023-03-31 (actual); primary completion 2024-06-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
INS068 injection
Intervention (Drug)
Insulin Glargine
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05702073
Content hash
9530e9b74de34e623352231557eebc97213c9749d3e45ba789cfd9a12618a90e